Delivery Order HHSN261201200020I-HHSN26100001
Award Date 9/20/12
Potential Completion Date 9/19/14
Potential Value $1.9K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
4
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
- The federal contract award with ID HHSN261200533000C was issued by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The contract, valued at $19,658,911.55, is for preclinical efficacy and intermediate endpoint assays. It is a definitive, cost-no-fee contract without a set-aside designation. The University of Oklahoma, as the prime contractor, will provide a range...
- This federal contract award is for a delivery order under the Preclinical Efficacy and Intermediate Endpoint Biomarkers indefinite delivery vehicle. The contract was awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma (OU) Univ Of Oklahoma Health Sciences Center Division. The contract is for "OTHER FUNCTIONS - PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS - CONTRACT ORIENTATION...
- This is a $1,029,991.00 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the University of Oklahoma Health Sciences Center. The order is for the "Further Evaluation of AMHR2-ED Antigens for Epithelial Ovarian Carcinoma" project, which aims to conduct research related to epithelial ovarian cancer. The award is part of the larger PREVENT Preclinical Drug Development Program (PREVENT), an Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle...
- This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "TARGETING CCK2R FOR PANCREATIC CANCER PREVENTION". The $474,197.46 contract is part of the NCI's Preclinical Agent Development Assays 2012-2016 program, which focuses on preclinical in vitro and in vivo agent development assays. The award does not have a set-aside designation. As...
- This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma Health Sciences Center Division. The contract is part of the NCI's "PREVENT Cancer Program (PREVENT)" and covers a "CONTRACT ORIENTATION AND KICK-OFF MEETING" with a period of performance from September 22, 2015 to December 31, 2015. The contract has a ceiling value of $4,217.44 and is a Delivery Order...
- The University of Oklahoma Health Sciences Center (OUHSC) was awarded a $909,993.85 firm fixed-price delivery order by the National Cancer Institute on September 21, 2020, for the evaluation of two different classes of compounds—STAT3 inhibitors and selective estrogen receptor modulators (SERMs)—for the prevention of urinary bladder cancer. This delivery order is issued under the PREVENT Cancer Preclinical Drug Development Program, an expansive National Cancer Institute Indefinite...
- This is a federal delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "OTHER FUNCTIONS - EFFICACY OF ASPIRIN AND NAPROXEN (SHORT-TERM-FREQUENT DOSING) IN COLORECTAL CANCER MODELS". The $770,757.36 contract is a cost-no-fee award that is part of the Preclinical Agent Development Assays 2012-2016 indefinite delivery/indefinite quantity (IDIQ) contract...
- This is a firm-fixed price delivery order awarded by the National Cancer Institute, a civilian agency, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The award, valued at $607,113.00, is for a pre-clinical study to investigate the use of aerosolized bexarotene as a chemopreventive agent against the three major subtypes of lung cancer in mouse models. This work is being performed under the Preclinical Agent Development Assays 2012-2016 indefinite delivery...